Wilson Disease Clinical Trial
— WILLYOfficial title:
Study of Retinal Vascular Parameters in Patients With Wilson's Disease
Verified date | March 2022 |
Source | Fondation Ophtalmologique Adolphe de Rothschild |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The rare disease reference center " Wilson disease and other rare copper-related diseases" of the Rothschild Foundation follows a large number of patients with Wilson's with varying degrees of impairment and located at different times of their care. Many people with Wilson's disease have a characteristic greenish-brown ring, known as Kayser-Fleischer, appearing at the periphery of the cornea due to a deposit of copper at the Descemet membrane. As a general rule, if the patient is compliant with his treatment, the ring usually disappears within a few years, although it may persist in some patients. However, apart from the stage of diagnosis, and the evolution of the ring, ophthalmological examinations are little used for the follow-up of these patients. The objective of this study is to describe the retinal parameters, in particular vascular with two new retinal imaging technologies (OCT-A :Optical Coherence Tomography-Angiography , Adaptive optics) in patients with Wilson's disease and to correlate them with the parameters of the usual follow-up of these patients (hepatic assessment, exchangeable plasma copper, neurological scores, compliance, etc.).
Status | Completed |
Enrollment | 124 |
Est. completion date | February 15, 2022 |
Est. primary completion date | January 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Wilson's disease with Ferenci score =4 Exclusion Criteria: - Neurological or behavioral handicap that does not allow for ophthalmological examinations - Hepatic decompensation that does not allow for ophthalmological examinations - Pregnant or breastfeeding woman |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Fondation A. de Rothschild | Paris |
Lead Sponsor | Collaborator |
---|---|
Fondation Ophtalmologique Adolphe de Rothschild |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measuring the width of the Kayser-Fleischer ring | OCT-B scan | Enrollment | |
Primary | Corrected visual acuity measurement | ETDRS | Enrollment | |
Primary | Intraocular pressure measurement (mmHg) | Enrollment | ||
Primary | Measurement of the thickness of the retinal nerve fibers layer (RNFL) | OCT-B | Enrollment | |
Primary | Measurement of the central avascular zone (in µm2) | OCT-A | Inclusion | |
Primary | Measurement of the capillary density of the superficial plexus (in%) | OCT-A | Enrollment | |
Primary | Measurement of the capillary density of the deep plexus (in%) | OCT-A | Enrollment | |
Primary | Measurement of photoreceptor density (per mm2) | Adaptive optics | Enrollment | |
Primary | Measurement of wall to lumen ratio (in %) | Adaptive optics | Enrollment | |
Primary | Measurement of the arterial wall section area (µm²) | Adaptive optics | Enrollment | |
Primary | Measurement of the diameter of the arterial lumen (µm) | Adaptive optics | Enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04573309 -
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
|
Phase 2 | |
Completed |
NCT03539952 -
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
|
Phase 3 | |
Active, not recruiting |
NCT04884815 -
Study of UX701 Gene Transfer for the Treatment of Wilson Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03659331 -
A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT04965571 -
Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
|
||
Terminated |
NCT05047523 -
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
|
Phase 3 | |
Completed |
NCT04526210 -
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
|
Phase 1 | |
Completed |
NCT00004338 -
Study of Zinc for Wilson Disease
|
Phase 4 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Completed |
NCT02273596 -
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
|
Phase 2 | |
Completed |
NCT02763215 -
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
|
||
Recruiting |
NCT05444127 -
Oral Health and Wilson's Disease: SOMAWI
|
||
Active, not recruiting |
NCT05783687 -
Real World Evidence Study in Subjects With Wilson's Disease
|
||
Terminated |
NCT04909346 -
Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
|
||
Completed |
NCT03867526 -
Establishment of Human Cellular Disease Models for Wilson Disease
|
||
Enrolling by invitation |
NCT03589820 -
Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure
|
N/A | |
Completed |
NCT04526197 -
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
|
Phase 1 | |
Not yet recruiting |
NCT06430359 -
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
|
||
Completed |
NCT04910581 -
rTMS in Wilson Disease Dysarthria
|
N/A |